To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

NCT05656079 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pegylated liposomal doxorubicin
DRUG: Epirubicin
DRUG: Cyclophosphamid
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Docetaxel

Sponsor

Shanghai Pudong Hospital

Collaborators

[object Object]